Full Press Release Details
LA JOLLA, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced its participation in the 2015 Wedbush PacGrow Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company and its clinical and preclinical programs on Wednesday, August 12, 2015 at 10:55 a.m. EDT (7:55 a.m. PDT). The conference will be held from Aug 11-12, 2015 in New York.
A live audio webcast and replay will be available in the Investors section of Kura's corporate website at www.kuraoncology.com.
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura's diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in a Phase 2 clinical study in patients with locally advanced tumors that carry HRAS mutations. The company's preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program. More information about Kura Oncology may be found at www.kuraoncology.com.